Prevalence of Chronic Metabolic Comorbidities in Acute Pancreatitis and Its Impact on Early Gastrointestinal Symptoms during Hospitalization: A Prospective Cohort Study

Abstract

<b><i>Background:</i></b> The prevalence of chronic comorbidities is increasing worldwide, and this has been paralleled by a growing interest in how these comorbidities affect patients with acute pancreatitis. The aim was to investigate the associations between pre-existing diabetes mellitus, obesity, metabolic syndrome, and gastrointestinal symptoms during the early course of acute pancreatitis. <b><i>Methods:</i></b> This was a prospective cohort study of patients with a primary diagnosis of acute pancreatitis. Study groups were formed based on the presence of metabolic comorbidities (pre-existing diabetes mellitus, obesity, and metabolic syndrome). Patient-reported outcomes (nausea, bloating, and abdominal pain) were collected prospectively every 24 h (including weekends and public holidays) over the first 72 h of hospitalization. <b><i>Results:</i></b> A total of 183 consecutive patients were enrolled. Of them, 111 (61%) had at least one major metabolic comorbidity. Patients with pre-existing diabetes mellitus and those with metabolic syndrome had worse nausea at 49–72 h of hospitalization (<i>p</i> = 0.017 and <i>p</i> = 0.012, respectively), but not at other time points. Bloating and abdominal pain did not differ between the study groupings throughout the study period. The studied patient-reported outcomes did not differ significantly between acute pancreatitis patients with and without obesity at any point in time. <b><i>Conclusion:</i></b> More than 3 out of 5 patients hospitalized for acute pancreatitis have at least one major chronic metabolic comorbidity. The presence of metabolic comorbidities does not considerably and consistently affect early gastrointestinal symptoms in patients with acute pancreatitis.

Immune-Enhancing Treatment among Acute Necrotizing Pancreatitis Patients with Metabolic Abnormalities: A Post Hoc Analysis of a Randomized Clinical Trial

“…5 A previous study revealed that more than 60% of AP patients had at least one major metabolic comorbidity, which was similar to our findings (53.9% hyperglycemia and 73.9% hypertriglyceridemia). 26 Among the components of metabolic syndrome, hyperglycemia and hypertriglyceridemia are the two most common metabolic abnormalities, which have frequently been reported to be associated with worse prognosis in AP. 8,9,27 Furthermore, both hyperglycemia and hypertriglyceridemia have been linked to impaired immune function, 10,12 potentially increasing the incidence of infection.…”

Relationship between Habitual Intake of Vitamins and New-Onset Prediabetes/Diabetes after Acute Pancreatitis

“…Therefore, antidiabetic medications were included in statistical models. This study also did not assess other possible confounders (e.g., inflammatory markers, intra-pancreatic fat deposition), which may affect glucose metabolism and insulin traits following AP [ 101 , 102 , 103 , 104 , 105 , 106 ]. Due to the relatively small sample size of the present study and results not being corrected for multiple testing, there is a risk of type I error.…”

Studying Myostatin as a Diagnostic Indicator in Sera of Iraqi Women with Metabolic Syndrome

“…40 female patients with metabolic syndrome and 40 healthy women, with age-range 35 to 60 years, participated in the study. The International Diabetes Federation reported in 2005 that the global consensus on metabolic syndrome served as the foundation for the diagnosis of metabolic syndrome 19,20 . In addition to a patient's BMI above 30 kg/m 2 , to be diagnosed with metabolic syndrome, any two of the following four requirements have to be satisfied: 1) Triglyceride levels are high (150 mg/dL) (or particular treatment for this lipid imbalance).…”